Lantheus Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $6.75B
- P/E (TTM)
- 24.2
- Dividend yield
- –
About Lantheus
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic imaging agents and radiopharmaceuticals. The company operates primarily through its radiopharmaceutical oncology and precision diagnostics businesses. Its commercial products include PYLARIFY, an imaging agent used in positron emission tomography scans, DEFINITY, an injectable imaging product, and Neuraceq. In addition, the business develops product candidates such as MK-6240 and NAV-4694. Lantheus serves healthcare providers, clinical development partners, and medical facilities that operate imaging equipment and diagnostic technologies.
The company is headquartered in Bedford, Massachusetts, and is incorporated in Delaware. Lantheus maintains an in-house manufacturing facility as well as an external network of positron emission tomography manufacturing facilities. The company provides products and conducts business activities for customers in the United States and international markets. Its operations also encompass corporate acquisitions, including Life Molecular Imaging and Evergreen Theragnostics.
Summary of the business section of Lantheus's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lantheus Holdings, Inc.
- Headquarters
- Bedford, MA
- Address
- 201 Burlington Road, South Building 01730
- Phone
- (978) 671-8001
- Employees
- 1,193, Dec 31, 2025
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- LNTH
- Exchange
- Nasdaq
- IPO date
- Jun 26, 2015
- Shares outstanding
- 65M, Aug 3, 2026
- Public float
- $4.27B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1521036
- CUSIP
- 516544103
- ISIN
- US5165441032
- LEI
- 5299005HUB5IOJGO7S39
- EIN
- 35-2318913
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mary Anne Heino | Executive Chair and CEO, Director | 587,968 |
| Brian A. Markison | CEO, Director | 232,420 |
| Robert J. Marshall Jr. | CFO and Treasurer | 122,071 |
| Ludger Dinkelborg | See Remarks | 33,195 |
| Kimberly Brown | Chief Accounting Officer | 13,263 |
| Daniel Niedzwiecki | See Remarks | 117,465 |
| Amanda Michelle Morgan | Chief Commercial Officer | 64,748 |
| Paul Blanchfield | President | 108,214 |
| Gerard Ber | Director | 27,118 |
| James H. Thrall | Director | 39,881 |
| Sam R. Leno | Director | 67,246 |
| Julie McHugh | Director | 30,099 |
| Gary J. Pruden | Director | 29,736 |
| Minnie Baylor-Henry | Director | 14,034 |
| Heinz Christoph Maeusli | Director | 30,014 |
| Julia Marie Eastland | Director | 8,019 |
| Phuong Khanh Morrow | Director | 7,237 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Brian AMarkison | $13.92M | $3.51M | $6.83M | $493 | $99 |
| FY2025 Mary Anne Heino | $2.17M | $135.13K | $6.83M | $493 | $99 |
| FY2024 Brian AMarkison | $787.60K | $9.64M | $4.20M | $663 | $94 |
| FY2024 Mary Anne Heino | $13.40M | $18.84M | $4.20M | $663 | $94 |
| FY2023 Mary Anne Heino | $12.58M | $19.69M | $3.96M | $460 | $89 |
| FY2022 Mary Anne Heino | $9.48M | $21.04M | $2.97M | $378 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 1,193 employees, of which 1,056 were located in the United States and 137 were located internationally.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 8, 2026 | Merger vote | Definitive merger proxy statement |
| Jul 22, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Apr 1, 2025 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 20, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 22, 2020 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 12, 2019 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 11, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jan 13, 2016 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Jun 26, 2015 | IPO | Initial public offering priced (424B4 prospectus) |
| Jul 25, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 23, 2014 | Name change | Name changed from Lantheus MI Holdings, Inc. to Lantheus Holdings, Inc. |